Apogee Therapeutics (APGE) Interest & Investment Income (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Interest & Investment Income data on file, last reported at $8.7 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 11.48% year-over-year to $8.7 million in Q1 2026; TTM through Mar 2026 was $23.4 million, a 10.27% decrease from a year earlier, with the FY2025 full-year figure at $30.0 million, down 13.56% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $8.7 million, roughly flat from $8.7 million in the prior quarter.
• Over the last five years, Interest & Investment Income for APGE reached as high as $9.7 million in Q3 2024 and fell as low as -$506000.0 in Q1 2024.
• Historically, Interest & Investment Income has averaged $4.8 million across 4 years, with a median of $5.9 million in 2023.
• Across the five-year window, Interest & Investment Income plunged 480.45% in 2024 and jumped 1649.41% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $5.4 million in 2023, then surged by 60.17% to $8.7 million in 2024, then rose by 0.58% to $8.7 million in 2025, then gained by 0.1% to $8.7 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $8.7 million in Q1 2026, $8.7 million in Q4 2025, and $6.3 million in Q3 2025.